1681 Stock Overview
Consun Pharmaceutical Group Limited, an investment holding company, researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China.
No risks detected for 1681 from our risk checks.
Consun Pharmaceutical Group Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$3.36|
|52 Week High||HK$8.00|
|52 Week Low||HK$3.00|
|1 Month Change||-12.95%|
|3 Month Change||-19.81%|
|1 Year Change||-5.09%|
|3 Year Change||-21.50%|
|5 Year Change||-47.99%|
|Change since IPO||-31.43%|
Recent News & Updates
|1681||HK Pharmaceuticals||HK Market|
Return vs Industry: 1681 exceeded the Hong Kong Pharmaceuticals industry which returned -37.4% over the past year.
Return vs Market: 1681 exceeded the Hong Kong Market which returned -28.8% over the past year.
|1681 Average Weekly Movement||6.1%|
|Pharmaceuticals Industry Average Movement||5.9%|
|Market Average Movement||6.4%|
|10% most volatile stocks in HK Market||12.6%|
|10% least volatile stocks in HK Market||3.1%|
Stable Share Price: 1681 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 1681's weekly volatility (6%) has been stable over the past year.
About the Company
Consun Pharmaceutical Group Limited, an investment holding company, researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China. The company operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. It offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles to treat proteinuria; Gadopentetate Dimeglumine injections for magnetic resonance image diagnostics of nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; and Iopamidol injections used for neuroradiology, angiography, and urography.
Consun Pharmaceutical Group Fundamentals Summary
|1681 fundamental statistics|
Is 1681 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|1681 income statement (TTM)|
|Cost of Revenue||CN¥547.48m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.81|
|Net Profit Margin||29.57%|
How did 1681 perform over the long term?See historical performance and comparison
Is 1681 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 1681?
Other financial metrics that can be useful for relative valuation.
|What is 1681's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 1681's PE Ratio compare to its peers?
|1681 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
2877 China Shineway Pharmaceutical Group
2348 Dawnrays Pharmaceutical (Holdings)
2633 Jacobson Pharma
6600 SciClone Pharmaceuticals (Holdings)
1681 Consun Pharmaceutical Group
Price-To-Earnings vs Peers: 1681 is good value based on its Price-To-Earnings Ratio (3.8x) compared to the peer average (5.9x).
Price to Earnings Ratio vs Industry
How does 1681's PE Ratio compare vs other companies in the HK Pharmaceuticals Industry?
Price-To-Earnings vs Industry: 1681 is good value based on its Price-To-Earnings Ratio (3.8x) compared to the Hong Kong Pharmaceuticals industry average (8.8x)
Price to Earnings Ratio vs Fair Ratio
What is 1681's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||3.8x|
|Fair PE Ratio||10.7x|
Price-To-Earnings vs Fair Ratio: 1681 is good value based on its Price-To-Earnings Ratio (3.8x) compared to the estimated Fair Price-To-Earnings Ratio (10.7x).
Share Price vs Fair Value
What is the Fair Price of 1681 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 1681 (HK$3.36) is trading below our estimate of fair value (HK$36.37)
Significantly Below Fair Value: 1681 is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Consun Pharmaceutical Group forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score3/6
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1681's forecast earnings growth (9.8% per year) is above the savings rate (1.6%).
Earnings vs Market: 1681's earnings (9.8% per year) are forecast to grow slower than the Hong Kong market (16.8% per year).
High Growth Earnings: 1681's earnings are forecast to grow, but not significantly.
Revenue vs Market: 1681's revenue (10.7% per year) is forecast to grow faster than the Hong Kong market (9.7% per year).
High Growth Revenue: 1681's revenue (10.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1681's Return on Equity is forecast to be high in 3 years time (21.4%)
Discover growth companies
How has Consun Pharmaceutical Group performed over the past 5 years?
Past Performance Score6/6
Past Performance Score 6/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1681 has high quality earnings.
Growing Profit Margin: 1681's current net profit margins (29.6%) are higher than last year (28.9%).
Past Earnings Growth Analysis
Earnings Trend: 1681's earnings have grown by 9% per year over the past 5 years.
Accelerating Growth: 1681's earnings growth over the past year (17.7%) exceeds its 5-year average (9% per year).
Earnings vs Industry: 1681 earnings growth over the past year (17.7%) exceeded the Pharmaceuticals industry 3.7%.
Return on Equity
High ROE: 1681's Return on Equity (20.9%) is considered high.
Discover strong past performing companies
How is Consun Pharmaceutical Group's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 1681's short term assets (CN¥3.1B) exceed its short term liabilities (CN¥1.2B).
Long Term Liabilities: 1681's short term assets (CN¥3.1B) exceed its long term liabilities (CN¥98.3M).
Debt to Equity History and Analysis
Debt Level: 1681 has more cash than its total debt.
Reducing Debt: 1681's debt to equity ratio has reduced from 34.1% to 15.3% over the past 5 years.
Debt Coverage: 1681's debt is well covered by operating cash flow (185.4%).
Interest Coverage: 1681 earns more interest than it pays, so coverage of interest payments is not a concern.
Discover healthy companies
What is Consun Pharmaceutical Group current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Forecast Dividend Yield
Dividend Yield vs Market
|Consun Pharmaceutical Group Dividend Yield vs Market|
|Company (Consun Pharmaceutical Group)||0%|
|Market Bottom 25% (HK)||3.0%|
|Market Top 25% (HK)||8.9%|
|Industry Average (Pharmaceuticals)||2.9%|
|Analyst forecast in 3 Years (Consun Pharmaceutical Group)||8.6%|
Notable Dividend: Unable to evaluate 1681's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 1681's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 1681's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 1681's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: 1681 is not paying a notable dividend for the Hong Kong market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 1681 has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Qian Li (57 yo)
Ms. Qian Li has been Vice Chairman at Consun Pharmaceutical Group Limited since November 2020 and serves as its Chief Executive Officer. Ms. Li served as the Chief Executive Officer of Consun Pharmaceutica...
CEO Compensation Analysis
|Qian Li's Compensation vs Consun Pharmaceutical Group Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||CN¥18m||CN¥1m|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||CN¥14m||CN¥1m|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||CN¥15m||CN¥1m|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||CN¥14m||CN¥975k|
|Sep 30 2018||n/a||n/a|
|Jun 30 2018||n/a||n/a|
|Mar 31 2018||n/a||n/a|
|Dec 31 2017||CN¥12m||CN¥973k|
|Sep 30 2017||n/a||n/a|
|Jun 30 2017||n/a||n/a|
|Mar 31 2017||n/a||n/a|
|Dec 31 2016||CN¥14m||CN¥974k|
|Sep 30 2016||n/a||n/a|
|Jun 30 2016||n/a||n/a|
|Mar 31 2016||n/a||n/a|
|Dec 31 2015||CN¥16m||CN¥974k|
Compensation vs Market: Qian's total compensation ($USD2.50M) is above average for companies of similar size in the Hong Kong market ($USD432.34K).
Compensation vs Earnings: Qian's compensation has increased by more than 20% in the past year.
Experienced Management: 1681's management team is considered experienced (2.6 years average tenure).
Experienced Board: 1681's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|17 Nov 21||BuyHK$2,217,880||Qian Li||Individual||607,638||HK$3.65|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Consun Pharmaceutical Group Limited's employee growth, exchange listings and data sources
- Name: Consun Pharmaceutical Group Limited
- Ticker: 1681
- Exchange: SEHK
- Founded: 1997
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: HK$2.649b
- Shares outstanding: 788.39m
- Website: https://www.chinaconsun.com
Number of Employees
- Consun Pharmaceutical Group Limited
- 71, Dongpeng Avenue
- Eastern section
- Guangdong Province
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|1681||SEHK (The Stock Exchange of Hong Kong Ltd.)||Yes||Ordinary Shares||HK||HKD||Dec 2013|
|C1P||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Dec 2013|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/02 00:00|
|End of Day Share Price||2022/09/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.